NDC 49643-302

Coast Maple Pollen

Acer Macrophyllum

Coast Maple Pollen is a Cutaneous; Intradermal; Subcutaneous Injection in the Non-standardized Allergenic category. It is labeled and distributed by Allermed Laboratories, Inc.. The primary component is Acer Macrophyllum Pollen.

Product ID49643-302_4f1be4f6-9f9e-5c19-e054-00144ff8d46c
NDC49643-302
Product TypeNon-standardized Allergenic
Proprietary NameCoast Maple Pollen
Generic NameAcer Macrophyllum
Dosage FormInjection
Route of AdministrationCUTANEOUS; INTRADERMAL; SUBCUTANEOUS
Marketing Start Date1974-03-12
Marketing CategoryBLA / BLA
Application NumberBLA102211
Labeler NameAllermed Laboratories, Inc.
Substance NameACER MACROPHYLLUM POLLEN
Active Ingredient Strength0 g/mL
Pharm ClassesNon-Standardized Pollen Allergenic Extract [EPC],Increased Histamine Release [PE],Cell-mediated Immunity [PE],Increased IgG Production [PE],Pollen [CS],Allergens [CS]
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 49643-302-05

5 mL in 1 VIAL, MULTI-DOSE (49643-302-05)
Marketing Start Date1974-03-12
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 49643-302-05 [49643030205]

Coast Maple Pollen INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

NDC 49643-302-10 [49643030210]

Coast Maple Pollen INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

NDC 49643-302-30 [49643030230]

Coast Maple Pollen INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

NDC 49643-302-50 [49643030250]

Coast Maple Pollen INJECTION
Marketing CategoryBLA
Application NumberBLA102211
Product TypeNON-STANDARDIZED ALLERGENIC
Marketing Start Date1974-03-12

Drug Details

Active Ingredients

IngredientStrength
ACER MACROPHYLLUM POLLEN.05 g/mL

Pharmacological Class

  • Non-Standardized Pollen Allergenic Extract [EPC]
  • Increased Histamine Release [PE]
  • Cell-mediated Immunity [PE]
  • Increased IgG Production [PE]
  • Pollen [CS]
  • Allergens [CS]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.